Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2016

Open Access 01-06-2016 | Review Article

Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options

Authors: Nina Sluiter, Erienne de Cuba, Riom Kwakman, Geert Kazemier, Gerrit Meijer, Elisabeth Atie te Velde

Published in: Clinical & Experimental Metastasis | Issue 5/2016

Login to get access

Abstract

Peritoneal dissemination is diagnosed in 10–25 % of colorectal cancer patients. Selected patients are treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. For these patients, earlier diagnosis, optimised selection criteria and a personalised approach are warranted. Biomarkers could play a crucial role here. However, little is known about possible candidates. Considering tumour cell adhesion as a key step in peritoneal dissemination, we aim to provide an overview of the functional importance of adhesion molecules in peritoneal dissemination and discuss the prognostic, diagnostic and therapeutic options of these candidate biomarkers. A systematic literature search was conducted according to the PRISMA guidelines. In 132 in vitro, ex vivo and in vivo studies published between 1995 and 2013, we identified twelve possibly relevant adhesion molecules in various cancers that disseminate peritoneally. The most studied molecules in tumour cell adhesion are integrin α2β1, CD44 s and MUC16. Furthermore, L1CAM, EpCAM, MUC1, sLex and Lex, chemokine receptors, Betaig-H3 and uPAR might be of clinical importance. ICAM1 was found to be less relevant in tumour cell adhesion in the context of peritoneal metastases. Based on currently available data, sLea and MUC16 are the most promising prognostic biomarkers for colorectal peritoneal metastases that may help improve patient selection. Different adhesion molecules appear expressed in haematogenous and transcoelomic spread, indicating two different attachment processes. However, our extensive assessment of available literature reveals that knowledge on metastasis-specific genes and their possible candidates is far from complete.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef
2.
Bird NC, Mangnall D, Majeed AW (2006) Biology of colorectal liver metastases: a review. J Surg Oncol 94(1):68–80PubMedCrossRef
3.
Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP (2006) Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 243(2):212–222PubMedPubMedCentralCrossRef
4.
Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89(12):1545–1550PubMedCrossRef
5.
Maggiori L, Bretagnol F, Ferron M, Chevalier Y, Panis Y (2011) Laparoscopic colorectal anastomosis using the novel Chex((R)) circular stapler: a case-control study. Colorectal Dis 13(6):711–715PubMedCrossRef
6.
Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z (2009) A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 24(6):677–685PubMedCrossRef
7.
Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, de Hingh IH, Punt CJ (2012) Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 38(7):617–623PubMedCrossRef
8.
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30(3):263–267PubMedPubMedCentralCrossRef
9.
Sugarbaker PH (1995) Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg 19(2):235–240PubMedCrossRef
10.
Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221(2):124–132PubMedPubMedCentralCrossRef
11.
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743PubMedCrossRef
12.
Verwaal VJ, Kusamura S, Baratti D, Deraco M (2008) The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 98(4):220–223PubMedCrossRef
13.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68PubMedCrossRef
14.
Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JH, te Velde EA et al (2013) Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20(13):4224–4230PubMedPubMedCentralCrossRef
15.
Verwaal VJ, Zoetmulder FA (2004) Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 30(3):280–285PubMedCrossRef
16.
de Cuba EM, Kwakman R, van Egmond M, Bosch LJ, Bonjer HJ, Meijer GA, te Velde EA (2012) Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalised treatment by use of biomarkers. Virchows Arch 461(3):231–243PubMedCrossRef
17.
Nakanishi H, Kodera Y, Yamamura Y, Ito S, Kato T, Ezaki T, Tatematsu M (2000) Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler. Int J Cancer 89(5):411–417PubMedCrossRef
18.
Kanellos I, Demetriades H, Zintzaras E, Mandrali A, Mantzoros I, Betsis D (2003) Incidence and prognostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum 46(4):535–539PubMedCrossRef
19.
Yamamoto S, Akasu T, Fujita S, Moriya Y (2003) Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol 33(1):33–37PubMedCrossRef
20.
Takebayashi K, Murata S, Yamamoto H, Ishida M, Yamaguchi T, Kojima M, Shimizu T, Shiomi H, Sonoda H, Naka S, Mekata E, Okabe H et al (2014) Surgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer. Ann Surg Oncol 21(6):1991–1997PubMedCrossRef
21.
Shepherd NA, Baxter KJ, Love SB (1997) The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 112(4):1096–1102PubMedCrossRef
22.
Hompes D, Tiek J, Wolthuis A, Fieuws S, Penninckx F, Van CE, D’Hoore A (2012) HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome. Ann Oncol 23(12):3123–3129PubMedCrossRef
23.
van der Bij GJ, Oosterling SJ, Beelen RH, Meijer S, Coffey JC, van Egmond M (2009) The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg 249(5):727–734PubMedCrossRef
24.
25.
26.
Strobel T, Cannistra SA (1999) Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 73(3):362–367PubMedCrossRef
27.
Casey RC, Oegema TRJ, Skubitz KM, Pambuccian SE, Grindle SM, Skubitz APN (2003) Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis 20(2):143–152PubMedCrossRef
28.
Nakashio T, Narita T, Akiyama S, Kasai Y, Kondo K, Ito K, Takagi H, Kannagi R (1997) Adhesion molecules and TGF-beta1 are involved in the peritoneal dissemination of NUGC-4 human gastric cancer cells. Int J Cancer 70(5):612–618PubMedCrossRef
29.
Nishii T, Yashiro M, Shinto O, Sawada T, Ohira M, Hirakawa K (2009) Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci 100(8):1397–1402PubMedCrossRef
30.
Hosono J, Narita T, Kimura N, Sato M, Nakashio T, Kasai Y, Nonami T, Nakao A, Takagi H, Kannagi R (1998) Involvement of adhesion molecules in metastasis of SW1990, human pancreatic cancer cells. J Surg Oncol 67(2):77–84PubMedCrossRef
31.
Kawamura T, Endo Y, Yonemura Y, Nojima N, Fujita H, Fujimura T, Obata T, Yamaguchi T, Sasaki T (2001) Significance of integrin alpha2/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. Int J Oncol 18(4):809–815PubMed
32.
Sakakura C, Hagiwara A, Nakanishi M, Shimomura K, Takagi T, Yasuoka R, Fujita Y, Abe T, Ichikawa Y, Takahashi S, Ishikawa T, Nishizuka I et al (2002) Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer 87(10):1153–1161PubMedPubMedCentralCrossRef
33.
Kishikawa T, Sakamoto M, Ino Y, Kubushiro K, Nozawa S, Hirohashi S (1995) Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. Invasion Metastasis 15(1–2):11–21PubMed
34.
Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP (1999) CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 154(5):1525–1537PubMedPubMedCentralCrossRef
35.
Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS (1996) Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer 67(5):695–701PubMedCrossRef
36.
Matsuoka T, Yashiro M, Nishimura S, Inoue T, Fujihara T, Sawada T, Kato Y, Seki S, Hirakawa YS, Chung K (2000) Increased expression of alpha2beta1-integrin in the peritoneal dissemination of human gastric carcinoma. Int J Mol Med 5(1):21–25PubMed
37.
Fishman DA, Kearns A, Chilukuri K, Bafetti LM, O’Toole EA, Georgacopoulos J, Ravosa MJ, Stack MS (1998) Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis 18(1):15–26PubMedCrossRef
38.
Buczek-Thomas JA, Chen N, Hasan T (1998) Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal 10(1):55–63PubMedCrossRef
39.
Ahmed N, Riley C, Rice G, Quinn M (2005) Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 22(5):391–402PubMedCrossRef
40.
Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TRJ, Skubitz APN (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 93(1):170–181PubMedCrossRef
41.
Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TRJ, Ruff LE, Skubitz AP (2001) Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 159(6):2071–2080PubMedPubMedCentralCrossRef
42.
Wagner BJ, Lob S, Lindau D, Horzer H, Guckel B, Klein G, Glatzle J, Rammensee HG, Brucher BL, Konigsrainer A (2011) Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and beta1 integrin. Int J Oncol 39(6):1593–1600PubMed
43.
Lin MT, Chang CC, Lin BR, Yang HY, Chu CY, Wu MH, Kuo ML (2007) Elevated expression of Cyr61 enhances peritoneal dissemination of gastric cancer cells through integrin alpha2beta1. J Biol Chem 282(47):34594–34604PubMedCrossRef
44.
Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T (2004) Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res 64(17):6065–6070PubMedCrossRef
45.
Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M (1996) Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer 74(9):1406–1412PubMedPubMedCentralCrossRef
46.
Oosterling SJ, van der Bij GJ, Bogels M, ten Raa S, Post JA, Meijer GA, Beelen RHJ, van Egmond M (2008) Anti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces. Ann Surg 247(1):85–94PubMedCrossRef
47.
Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T (2006) Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol 7:8PubMedPubMedCentralCrossRef
48.
Mino K, Ozaki M, Nakanishi K, Haga S, Sato M, Kina M, Takahashi M, Takahashi N, Kataoka A, Yanagihara K, Ochiya T, Kamiyama T et al (2011) Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci 102(5):1052–1058PubMedCrossRef
49.
Jansen M, Jansen PL, Otto J, Kirtil T, Neuss S, Treutner KH, Schumpelick V (2006) The inhibition of tumor cell adhesion on human mesothelial cells (HOMC) by phospholipids in vitro. Langenbecks Arch Surg 391(2):96–101PubMedCrossRef
50.
Yokoyama Y, Ramakrishnan S (2007) Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer 121(11):2402–2409PubMedCrossRef
51.
Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J (1995) Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol 58(2):216–225PubMedCrossRef
52.
Maubant S, Cruet-Hennequart S, Dutoit S, Denoux Y, Crouet H, Henry-Amar M, Gauduchon P (2005) Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J Mol Histol 36(1–2):119–129PubMedCrossRef
53.
Kokenyesi R, Murray KP, Benshushan A, Huntley ED, Kao MS (2003) Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol 89(1):60–72PubMedCrossRef
54.
Fukuda K, Saikawa Y, Yagi H, Wada N, Takahashi T, Kitagawa Y (2012) Role of integrin alpha1 subunits in gastric cancer patients with peritoneal dissemination. Mol Med Rep 5(2):336–340PubMed
55.
Heyman L, Kellouche S, Fernandes J, Dutoit S, Poulain L, Carreiras F (2008) Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol 29(4):231–244PubMedCrossRef
56.
Carreiras F, Lehmann M, Sichel F, Marvaldi J, Gauduchon P, le Talaer JY (1995) Implication of the alpha v beta 3 integrin in the adhesion of the ovarian-adenocarcinoma cell line IGROV1. Int J Cancer 63(4):530–536PubMedCrossRef
57.
Matsuoka T, Hirakawa K, Chung YS, Yashiro M, Nishimura S, Sawada T, Saiki I, Sowa M (1998) Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis 16(4):381–388PubMedCrossRef
58.
Liu J, Geng X, Li Y (2016) Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis. Tumour Biol. Epub ahead of print
59.
Ceelen WP, Bracke ME (2009) Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 10(1):72–79PubMedCrossRef
60.
Hirabayashi Y, Yamaguchi K, Shiraishi N, Adachi Y, Saiki I, Kitano S (2004) Port-site metastasis after CO2 pneumoperitoneum: role of adhesion molecules and prevention with antiadhesion molecules. Surg Endosc 18(7):1113–1117PubMedCrossRef
61.
Akita N, Maruta F, Seymour LW, Kerr DJ, Parker AL, Asai T, Oku N, Nakayama J, Miyagawa S (2006) Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci 97(10):1075–1081PubMedCrossRef
62.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61(7):1303–1313PubMedCrossRef
63.
Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP (1996) Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol 148(6):1733–1740PubMedPubMedCentral
64.
Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S (2001) Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 91(1):67–75PubMedCrossRef
65.
Gardner MJ, Catterall JB, Jones LM, Turner GA (1996) Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Clin Exp Metastasis 14(4):325–334PubMedCrossRef
66.
Catterall JB, Jones LM, Turner GA (1999) Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan. Clin Exp Metastasis 17(7):583–591PubMedCrossRef
67.
Li CZ, Liu B, Wen ZQ, Li HY (2008) Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol (Praha) 54(6):180–186
68.
Strobel T, Swanson L, Cannistra SA (1997) In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res 57(7):1228–1232PubMed
69.
Ziprin P, Ridgway PF, Pfistermuller KLM, Peck DH, Darzi AW (2003) ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes 10(3):141–154PubMedCrossRef
70.
Cannistra SA, DeFranzo B, Niloff J, Ottensmeir C (1995) Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res 1(3):333–342PubMed
71.
Catterall JB, Gardner MJ, Jones LM, Turner GA (1997) Binding of ovarian cancer cells to immobilized hyaluronic acid. Glycoconj J 14(7):867–869PubMedCrossRef
72.
van Grevenstein WMU, Hofland LJ, Jeekel J, van Eijck CHJ (2006) The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas 32(4):396–402PubMedCrossRef
73.
ten Raa S, van Grevenstein HMU, ten Kate M, Mangundap KM, Hofland LJ, Jeekel H, Sluiter W, van Eijck CHJ (2007) The influence of reactive oxygen species on the adhesion of pancreatic carcinoma cells to the peritoneum. Cell Adhes Migr 1(2):77–83CrossRef
74.
Yu G, Tang B, Yu PW, Peng ZH, Qian F, Sun G (2010) Systemic and peritoneal inflammatory response after laparoscopic-assisted gastrectomy and the effect of inflammatory cytokines on adhesion of gastric cancer cells to peritoneal mesothelial cells. Surg Endosc 24(11):2860–2870PubMedCrossRef
75.
Chen H, Hao J, Wang L, Li Y (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101(3):432–440PubMedPubMedCentralCrossRef
76.
Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000) Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma—diagnostic and prognostic implications. Clin Exp Metastasis 18(2):197–202PubMedCrossRef
77.
Kayastha S, Freedman AN, Piver MS, Mukkamalla J, Romero-Guittierez M, Werness BA (1999) Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 5(5):1073–1076PubMed
78.
Yamamichi K, Uehara Y, Kitamura N, Nakane Y, Hioki K (1998) Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 79(3):256–262PubMedCrossRef
79.
Sillanpaa S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM (2003) CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res 9(14):5318–5324PubMed
80.
Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M (2008) Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 15(2):526–534PubMedCrossRef
81.
Yamaguchi K, Hirabayashi Y, Shiromizu A, Shiraishi N, Adachi Y, Kitano S (2001) Enhancement of port site metastasis by hyaluronic acid under CO2 pneumoperitoneum in a murine model. Surg Endosc 15(5):504–507PubMedCrossRef
82.
Tan B, Wang JH, Wu QD, Kirwan WO, Redmond HP (2001) Sodium hyaluronate enhances colorectal tumour cell metastatic potential in vitro and in vivo. Br J Surg 88(2):246–250PubMedCrossRef
83.
Jones LM, Gardner MJ, Catterall JB, Turner GA (1995) Hyaluronic acid secreted by mesothelial cells: a natural barrier to ovarian cancer cell adhesion. Clin Exp Metastasis 13(5):373–380PubMedCrossRef
84.
Li SD, Howell SB (2010) CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm 7(1):280–290PubMedCrossRef
85.
Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Melendez-Alafort L, Mazzi U, Zanovello P, Rosato A (2008) A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 14(11):3598–3606PubMedCrossRef
86.
Serafino A, Zonfrillo M, Andreola F, Psaila R, Mercuri L, Moroni N, Renier D, Campisi M, Secchieri C, Pierimarchi P (2011) CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targ 11(5):572–585CrossRef
87.
Hubbard SC, Burns JW (2002) Effects of a hyaluronan-based membrane (seprafilm) on intraperitoneally disseminated human colon cancer cell growth in a nude mouse model. Dis Colon Rectum 45(3):334–341PubMedCrossRef
88.
Pucciarelli S, Codello L, Rosato A, Del Bianco P, Vecchiato G, Lise M (2003) Effect of antiadhesive agents on peritoneal carcinomatosis in an experimental model. Br J Surg 90(1):66–71PubMedCrossRef
89.
Haverlag R, van Rossen ME, van den Tol MP, Bonthuis F, Marquet RL, Jeekel J (1999) Hyaluronate-based coating solution for prevention of surgical adhesions has no major effect on adhesion and growth of intraperitoneal tumour cells. Eur J Surg 165(8):791–795PubMedCrossRef
90.
Kokenyesi R (2001) Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. J Cell Biochem 83(2):259–270PubMedCrossRef
91.
Jacobi CA, Ordemann J, Bohm B, Zieren HU, Sabat R, Muller JM (1997) Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. Am J Surg 174(3):359–363PubMedCrossRef
92.
Paschos KA, Canovas D, Bird NC (2009) The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 21(5):665–674PubMedCrossRef
93.
Gardner MJ, Jones LM, Catterall JB, Turner GA (1995) Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 91(2):229–234PubMedCrossRef
94.
Alkhamesi NA, Ziprin P, Pfistermuller K, Peck DH, Darzi AW (2005) ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis 22(6):449–459PubMedCrossRef
95.
Ziprin P, Alkhamesi NA, Ridgway PF, Peck DH, Darzi AW (2004) Tumour-expressed CD43 (sialophorin) mediates tumour mesothelial cell adhesion. Biol Chem 385(8):755–761PubMedCrossRef
96.
Tanaka H, Yashiro M, Sunami T, Ohira M, Hirakawa Y (2002) Lipid-mediated gene transfection of intercellular adhesion molecule-1 suppresses the peritoneal metastasis of gastric carcinoma. Int J Mol Med 10(5):613–617PubMed
97.
Jones EY, Harlos K, Bottomley MJ, Robinson RC, Driscoll PC, Edwards RM, Clements JM, Dudgeon TJ, Stuart DI (1995) Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 A resolution. Nature 373(6514):539–544PubMedCrossRef
98.
Arlt MJE, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P, Kruger A (2006) Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 66(2):936–943PubMedCrossRef
99.
Stoeck A, Schlich S, Issa Y, Gschwend V, Wenger T, Herr I, Marme A, Bourbie S, Altevogt P, Gutwein P (2006) L1 on ovarian carcinoma cells is a binding partner for neuropilin-1 on mesothelial cells. Cancer Lett 239(2):212–226PubMedCrossRef
100.
Kodera Y, Nakanishi H, Ito S, Misawa K, Ito Y, Nakayama G, Koike M, Fujiwara M, Yamamura Y, Nakao A (2009) Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer. Anticancer Res 29(10):4033–4039PubMed
101.
Knogler K, Grunberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S, Altevogt P, Fogel M, Schubiger PA, Novak-Hofer I (2007) Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 13(2 Pt 1):603–611PubMedCrossRef
102.
Asao T, Nagamachi Y, Morinaga N, Shitara Y, Takenoshita S, Yazawa S (1995) Fucosyltransferase of the peritoneum contributed to the adhesion of cancer cells to the mesothelium. Cancer 75(6 Suppl):1539–1544PubMedCrossRef
103.
Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W, Henne-Bruns D, Kremer B, Juhl H (1998) Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 227(3):372–379PubMedPubMedCentralCrossRef
104.
Ikeda Y, Mori M, Kamakura T, Saku M, Sugimachi K (1995) Immunohistochemical expression of sialyl Tn and sialyl Lewis(a) antigens in stromal tissue correlates with peritoneal dissemination in stage IV human gastric cancer. Eur J Surg Oncol 21(2):168–175PubMedCrossRef
105.
Kiguchi K, Iwamori M, Mochizuki Y, Kishikawa T, Tsukazaki K, Saga M, Amemiya A, Nozawa S (1998) Selection of human ovarian carcinoma cells with high dissemination potential by repeated passage of the cells in vivo into nude mice, and involvement of Le(x)-determinant in the dissemination potential. Jpn J Cancer Res 89(9):923–932PubMedCrossRef
106.
Gebauer F, Wicklein D, Stubke K, Nehmann N, Schmidt A, Salamon J, Peldschus K, Nentwich MF, Adam G, Tolstonog G, Bockhorn M, Izbicki JR et al (2013) Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp–/rag2– mice. Gut 62(5):741–750PubMedCrossRef
107.
Aubert M, Panicot-Dubois L, Crotte C, Sbarra V, Lombardo D, Sadoulet MO, Mas E (2000) Peritoneal colonization by human pancreatic cancer cells is inhibited by antisense FUT3 sequence. Int J Cancer 88(4):558–565PubMedCrossRef
108.
Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M (2001) Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 22(5):318–322PubMedCrossRef
109.
Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, Kasahara M, Mochizuki F, Kasakura Y, Yamagata M (2000) Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 3(4):177–186PubMedCrossRef
110.
Nakamori S, Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O, Kabuto T, Sasaki Y, Kameyama M, Ishiguro S, Irimura T (1997) Expression of carbohydrate antigen sialyl Le(a): a new functional prognostic factor in gastric cancer. J Clin Oncol 15(2):816–825PubMed
111.
Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K, Ishikawa H (2002) Difference in prognostic value between sialyl Lewis(a) and sialyl Lewis(x) antigen levels in the preoperative serum of gastric cancer patients. J Clin Gastroenterol 34(4):408–415PubMedCrossRef
112.
Ikeda Y, Oomori H, Koyanagi N, Mori M, Kamakura T, Minagawa S, Tateishi H, Sugimachi K (1995) Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncology 52(6):483–486PubMedCrossRef
113.
Nakata B, Hirakawa YS, Chung K, Kato Y, Yamashita Y, Maeda K, Onoda O, Sawada T, Sowa M (1998) Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 83(12):2488–2492PubMedCrossRef
114.
Hwang GI, Yoo CH, Sohn BH, Shin JH, Park YL, Kim HD, Kim YS, Han WK, Pae WK (2004) Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat 36(3):178–181PubMedPubMedCentralCrossRef
115.
Yamamoto M, Baba H, Kakeji Y, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T, Maehara Y (2004) Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer. Oncology 67(1):19–26PubMedCrossRef
116.
Yang SH, Lin JK, Lai CR, Chen CC, Li AF-Y, Liang WY, Jiang JK (2004) Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol 87(4):167–173PubMedCrossRef
117.
Park IJ, Choi GS, Jun SH (2009) Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res 29(10):4303–4308PubMed
118.
Li Y, Yang Y, Lu M, Shen L (2011) Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology 58(112):2166–2170PubMedCrossRef
119.
Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H (2003) The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 6(3):142–145PubMedCrossRef
120.
Marrelli D, Pinto E, De SA, Farnetani M, Garosi L, Roviello F (2001) Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 181(1):16–19PubMedCrossRef
121.
122.
Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279(10):9190–9198PubMedCrossRef
123.
Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5(1):50PubMedPubMedCentralCrossRef
124.
Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N (2007) Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett 247(1):130–136PubMedPubMedCentralCrossRef
125.
Bergan L, Gross JA, Nevin B, Urban N, Scholler N (2007) Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/mesothelin-dependent cell attachment. Cancer Lett 255(2):263–274PubMedCrossRef
126.
Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piche A, Rancourt C (2011) MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 121(3):434–443PubMedCrossRef
127.
Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J (2012) Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 15(2):154–161PubMedCrossRef
128.
Fujimura T, Kinami S, Ninomiya I, Kitagawa H, Fushida S, Nishimura G, Kayahara M, Shimizu K, Ohta T, Miwa K (2002) Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Endoscopy 34(7):569–574PubMedCrossRef
129.
Yamamoto M, Baba H, Toh Y, Okamura T, Maehara Y (2007) Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol 133(7):471–476PubMedCrossRef
130.
Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y (2007) Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 105(3):695–702PubMedCrossRef
131.
van Elssen CH, Frings PW, Bot FJ, van de Vijver KK, Huls MB, Meek B, Hupperets P, Germeraad WT, Bos GM (2010) Expression of aberrantly glycosylated mucin-1 in ovarian cancer. Histopathology 57(4):597–606PubMedCrossRef
132.
Nakanishi H, Kodera Y, Yamamura Y, Kuzuya K, Nakanishi T, Ezaki T, Tatematsu M (1999) Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol 43(Suppl):S32–S36PubMedCrossRef
133.
Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, Perkins AC, Kearsley JH, Li Y (2011) Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS ONE 6(9):e24405PubMedPubMedCentralCrossRef
134.
Oei ALM, Moreno M, Verheijen RHM, Sweep FCGJ, Thomas CMG, Massuger LFAG, von Mensdorff-Pouilly S (2008) Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int J Cancer 123(8):1848–1853PubMedCrossRef
135.
Patriarca C, Macchi RM, Marschner AK, Mellstedt H (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38(1):68–75PubMedCrossRef
136.
Imano M, Itoh T, Satou T, Yasuda A, Nishiki K, Kato H, Shiraishi O, Peng Y, Shinkai M, Tsubaki M, Yasuda T, Imamoto H et al (2012) High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer. Targ Oncol 8(4):231–235CrossRef
137.
Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R et al (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65(7):2882–2889PubMedCrossRef
138.
Strohlein MA, Lordick F, Ruttinger D, Grutzner KU, Schemanski OC, Jager M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM (2011) Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie 34(3):101–108PubMedCrossRef
139.
Rossi Del Monte S, Ranieri D, Mazzetta F, Kazemi Nava A, Raffa S, Torrisi MR, Ziparo V (2012) Free peritoneal tumor cells detection in gastric and colorectal cancer patients. J Surg Oncol 106(1):17–23PubMedCrossRef
140.
Kim M, Rooper L, Xie J, Kajdacsy-Balla AA, Barbolina MV (2012) Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res 10(1):11–24PubMedPubMedCentralCrossRef
141.
Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F (2008) Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122(1):91–99PubMedCrossRef
142.
Li Z, Miao Z, Jin G, Li X, Li H, Lv Z, Xu HM (2012) betaig-h3 supports gastric cancer cell adhesion, migration and proliferation in peritoneal carcinomatosis. Mol Med Rep 6(3):558–564PubMed
143.
Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK (2011) Transforming growth factor-beta-induced protein secreted by peritoneal cancer cells increases the metastatic potential of ovarian cancer cells. Int J Cancer 128:1570–1584PubMedCrossRef
144.
Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC (2007) Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171(2):386–395PubMedPubMedCentralCrossRef
145.
Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11(2):162–171PubMedCrossRef
146.
Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID (2007) Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 20(2):221–232PubMedCrossRef
147.
Verghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR (2007) Site-specific gene expression profiles and novel molecular prognositc factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol 14(12):3460–3471CrossRef
148.
Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4(4):309–314PubMedCrossRef
149.
Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope CG, Risberg B, Kopolovic J (2003) AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90(2):248–257PubMedCrossRef
150.
Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M (1996) CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Jpn J Cancer Res 87(12):1235–1244PubMedCrossRef
151.
Grzesiak JJ, Tran Cao HS, Burton DW, Kaushal S, Vargas F, Clopton P, Snyder CS, Deftos LJ, Hoffman RM, Bouvet M (2011) Knockdown of the beta(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int J Cancer 129(12):2905–2915PubMedPubMedCentralCrossRef
152.
Metadata
Title
Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options
Authors
Nina Sluiter
Erienne de Cuba
Riom Kwakman
Geert Kazemier
Gerrit Meijer
Elisabeth Atie te Velde
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2016
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9791-0

Other articles of this Issue 5/2016

Clinical & Experimental Metastasis 5/2016 Go to the issue

Research Paper

Methylation-mediated downregulation of long noncoding RNA LOC100130476 in gastric cardia adenocarcinoma

Research Paper

CXCL12 is a key regulator in tumor microenvironment of cervical cancer: an in vitro study

Research Paper

Prion protein binding to HOP modulates the migration and invasion of colorectal cancer cells

Research Paper

Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94

Research Paper

Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA

Research Paper

Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits